Hints and tips:
...“It’s on the sponsor to defend their portfolio,” said John Kline, managing director of New Mountain Capital....
...Emma Walmsley, who will shortly take up her new role as chief executive at GlaxoSmithKline, is a prime example....
...Several companies have announced plans for investment and job creation since Brexit, including GlaxoSmithKline and McDonald’s this week....
...The question of how to promote strong university-industry links is under study in an investigation led by Andrew Witty, chief executive of GlaxoSmithKline (GSK), the pharmaceutical group....
...That is roughly in line with similar deals carried out by multinationals, most recently drugmaker GlaxoSmithKline which late last year lifted its 43.2 per cent stake in its pivotal Indian division, GlaxoSmithKline...
...It is against this background that the Chinese authorities this week accused UK drugmaker GlaxoSmith-Kline of being the ringleader in a half-a-billion-dollar bribery scandal involving 700 companies....
...Last week, GlaxoSmithKline strengthened its commitment by signing a partnership with Amicus, a specialist US company with its own portfolio of next-generation experimental drugs for Fabry disease....
...The defection of GlaxoSmith-Kline has left it with only eight corporate clients in the FTSE 100, including Morrison, Rolls-Royce and Tullow Oil....
...The FTSE 100 closed 0.76 points higher at 5,568.72 as GlaxoSmith-Kline gained 2 per cent to £14.28 and Imperial Tobacco added 1.3 per cent to £23.34....
...From student days studying glaciers and urban agglomerations, Simon Dingemans now travels the world, guided by his spreadsheet in a search for improved returns for GlaxoSmith-Kline, the UK-based pharmaceutical...
...Google, the internet search group, and GlaxoSmithKline, the pharmaceutical company, are among those attracted to the region in recent years....
...In late December, Proximagen bought two drug development programmes spun off from GlaxoSmith Kline, which had earlier in the year decided to withdraw from certain types of neuroscience research....
...Mr Kindler also placed some big new “bets”: investing in regenerative medicine and high value “orphan drugs”; and agreeing risk- and revenue-sharing deals with Bristol-Myers Squibb and GlaxoSmith-Kline....
...Andrew Witty, the chief executive of GlaxoSmith-Kline, the UK-based pharmaceutical group, is to join the panel, as is Paul Walsh from Diageo. Both performed similar roles for the previous government....
...Richard Kline, Occidental spokesman, declined to comment....
...UK regulators have called for the withdrawal across Europe of GlaxoSmith-Kline’s diabetes drug Avandia, dealing a blow to the pharmaceuticals group in its home market....
...Simon Dingemans, one of Goldman Sachs’ veteran dealmakers in London, is leaving the bank to join drugmaker GlaxoSmith-Kline as chief financial officer at a time when global mergers and acquisitions activity...
...It also failed – like other countries – to impose on GlaxoSmith-Kline, its main vaccine provider, a “break clause” to reduce its orders once the vaccine proved more potent and the virus milder than initially...
...Europe-based pharmaceuticals groups led by GlaxoSmithKline are outperforming US and Japanese rivals in efforts to ensure medicines reach the poor, according to an independent evaluation to be published...
...Nick Raynor, investment adviser at the Share Center urges private income-seeking investors to “crystallise their losses and move on” to stocks paying secure dividends such as GlaxoSmith-Kline and Vodafone...
...Although companies such as Shell and GlaxoSmith-Kline have shown support, if so far limited, for the project, perhaps the biggest barrier to progress is posed by the Venezuelan government....
...His company, alongside Sanofi-Aventis of France and GlaxoSmithKline of the UK, as well as smaller producers including Baxter of the US, AstraZeneca in the UK and CSL in Australia, were under pressure to...
...Andrew Witty, the chief executive of GlaxoSmithKline, has made much of shifting his group away from “white pills in western markets”, most recently this year pushing down this traditional segment of the...
...When the chief executive of GlaxoSmithKline presented his company’s most recent financial results last month, he gave a sense of how the UK’s biggest drugmaker – and the industry more generally – is responding...
...To the south of Cambridge, a new science park is being built on GlaxoSmith-Kline’s Stevenage site. To the west is Colworth Science Park in Bedfordshire....
International Edition